Societe Generale’s Pacira BioSciences PCRX Stock Holding History

Societe Generale’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$287K	Buy	+8,499	New	+$418K	﹤0.01%	1961

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Societe Generale's PCRX Position: Q2 2016 in Review

Societe Generale opened a new position in Pacira BioSciences (PCRX) in Q2 2016: 8,499 shares worth $287K. The stake represents ﹤0.01% of the portfolio and ranks #1961 among its holdings.

183 funds tracked by Wall St. Rank hold PCRX as of Q2 2016.

Societe Generale held 8,499 shares of Pacira BioSciences worth $287K as of Q2 2016.
Pacira BioSciences was a new Societe Generale position in Q2 2016.
Pacira BioSciences made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #1961 holding.
183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.